Association between hTERT activation by HPV E6 proteins and oncogenic risk

Virology

Volumn 433, Issue 1, 2012, Pages 216-219

  Van Doorslaer, Koenraad ^a,b   Burk, Robert D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Epidemiology; Evolution; HTERT; Oncogenesis; Papillomavirus

Indexed keywords

MYC PROTEIN; PROTEIN E6; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CANCER RISK; CARCINOGENICITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 51; NONHUMAN; PHENOTYPE; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN ISOLATION; UPREGULATION; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; WART VIRUS;

ALPHAPAPILLOMAVIRUS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; GENES, REPORTER; HUMANS; LUCIFERASES; ONCOGENE PROTEINS, VIRAL; PHYLOGENY; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; REPRESSOR PROTEINS; RISK; TELOMERASE;

ALPHAPAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 84866180805     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.08.006     Document Type: Article

References (40)

1. Anderson S., Shera K., Ihle J., Billman L., Goff B., Greer B., Tamimi H., McDougall J., Klingelhutz A. Telomerase activation in cervical cancer. Am. J. Pathol. 1997, 151:25-31.
2. Bernard H.U., Burk R.D., Chen Z., van Doorslaer K., Zur Hausen H., de Villiers E.M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401:70-79.
3. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Benbrahim-Tallaa L., Guha N., Freeman C., Galichet L., Cogliano V. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 2009, 10:321-322.
4. Boyer S.N., Wazer D.E., Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996, 56:4620-4624.
5. Branca M., Giorgi C., Ciotti M., Santini D., Di B.L., Costa S., Benedetto A., Bonifacio D., Di B.P., Paba P., Accardi L., Mariani L., Ruutu M., Syrjanen S., Favalli C., Syrjanen K. Upregulation of telomerase (hTERT) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus, virus persistence, or disease outcome in cervical cancer. Diagn.Cytopathol. 2006, 34:739-748.
6. Cerni C. Telomeres, telomerase, and myc. An update. Mutat. Res. 2000, 462:31-47.
7. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H. Classification of papillomaviruses. Virology 2004, 324:17-27.
8. Frost M., Bobak J.B., Gianani R., Kim N., Weinrich S., Spalding D.C., Cass L.G., Thompson L.C., Enomoto T., Uribe-Lopez D., Shroyer K.R. Localization of telomerase hTERT protein and hTR in benign mucosa, dysplasia, and squamous cell carcinoma of the cervix. Am. J. Clin. Pathol. 2000, 114:726-734.
9. Fu L., Van Doorslaer K., Chen Z., Ristriani T., Masson M., Trave G., Burk R.D. Degradation of p53 by human Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity. PLoS ONE 2010, 5:e12816.
10. Garbe J., Wong M., Wigington D., Yaswen P., Stampfer M.R. Viral oncogenes accelerate conversion to immortality of cultured conditionally immortal human mammary epithelial cells. Oncogene 1999, 18:2169-2180.
11. Gewin L., Galloway D.A. E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J. Virol. 2001, 75:7198-7201.
12. Gewin L., Myers H., Kiyono T., Galloway D.A. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 2004, 18:2269-2282.
13. Gorham H., Yoshida K., Sugino T., Marsh G., Manek S., Charnock M., Tarin D., Goodison S. Telomerase activity in human gynaecological malignancies. J. Clin. Pathol. 1997, 50:501-504.
14. Gouy M., Guindon S., Gascuel O. SeaView version 4: a multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol. Biol. Evol. 2010, 27:221-224.
15. Helt A.M., Galloway D.A. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J. Virol. 2001, 75:6737-6747.
16. IARC, 2012. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 100B: A Review of Human Carcinogens: Biological Agents.
17. Iwasaka T., Zheng P.S., Yokoyama M., Fukuda K., Nakao Y., Sugimori H. Telomerase activation in cervical neoplasia. Obstet. Gynecol. 1998, 91:260-262.
18. James M.A., Lee J.H., Klingelhutz A.J. HPV16-E6 associated hTERT promoter acetylation is E6AP dependent, increased in later passage cells and enhanced by loss of p300. Int. J. Cancer 2006, 119:1878-1885.
19. Katoh K., Misawa K., Kuma K., Miyata T. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 2002, 30:3059-3066.
20. Kiyono T., Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., Klingelhutz A.J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998, 396:84-88.
21. Klingelhutz A.J., Foster S.A., McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996, 380:79-82.
22. Klingelhutz A.J., Roman A. Cellular transformation by human papillomaviruses: Lessons learned by comparing high- and low-risk viruses. Virology 2012, 424:77-98.
23. Liu X., Dakic A., Zhang Y., Dai Y., Chen R., Schlegel R. HPV E6 protein interacts physically and functionally with the cellular telomerase complex. Proc. Natl. Acad. Sci. USA 2009, 106:18780-18785.
24. Liu X., Yuan H., Fu B., Disbrow G.L., Apolinario T., Tomaic V., Kelley M.L., Baker C.C., Huibregtse J., Schlegel R. The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J. Biol. Chem. 2005, 280:10807-10816.
25. Lundberg A.S., Randell S.H., Stewart S.A., Elenbaas B., Hartwell K.A., Brooks M.W., Fleming M.D., Olsen J.C., Miller S.W., Weinberg R.A., Hahn W.C. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 2002, 21:4577-4586.
26. McMurray H.R., McCance D.J. Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16 E6/E7. J. Virol. 2004, 78:5698-5706.
27. Nylander J.A., Wilgenbusch J.C., Warren D.L., Swofford D.L. AWTY (are we there yet?): a system for graphical exploration of MCMC convergence in Bayesian phylogenetics. Bioinformatics 2008, 24:581-583.
28. Oh S.T., Kyo S., Laimins L.A. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J. Virol. 2001, 75:5559-5566.
29. Pao C.C., Tseng C.J., Lin C.Y., Yang F.P., Hor J.J., Yao D.S., Hsueh S., Hsueh S. Differential expression of telomerase activity in human cervical cancer and cervical intraepithelial neoplasia lesions. J. Clin. Pathol. 1997, 15:1932-1937.
30. Posada D., Crandall K.A. MODELTEST: testing the model of DNA substitution. Bioinformatics 1998, 14:817-818.
31. Ronquist F., Huelsenbeck J.P. MrBayes 3: Bayesian phylogenetic inference under mixed models. Bioinformatics 2003, 19:1572-1574.
32. Schiffman M., Clifford G., Buonaguro F.M. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect. Agent Cancer 2009, 4:8.
33. Schiffman M., Herrero R., DeSalle R., Hildesheim A., Wacholder S., Rodriguez A.C., Bratti M.C., Sherman M.E., Morales J., Guillen D., Alfaro M., Hutchinson M., Wright T.C., Solomon D., Chen Z., Schussler J., Castle P.E., Burk R.D. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005, 337:76-84.
34. Stoppler H., Hartmann D.P., Sherman L., Schlegel R. The human papillomavirus type 16 E6 and E7 oncoproteins dissociate cellular telomerase activity from the maintenance of telomere length. J. Biol. Chem. 1997, 272:13332-13337.
35. Takakura M., Kyo S., Kanaya T., Hirano H., Takeda J., Yutsudo M., Inoue M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 1999, 59:551-557.
36. Van Doorslaer K., Burk R.D. Evolution of human Papillomavirus carcinogenicity. Adv. Virus Res. 2010, 77:41-62.
37. Veldman T., Horikawa I., Barrett J.C., Schlegel R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J. Virol. 2001, 75:4467-4472.
38. Veldman T., Liu X., Yuan H., Schlegel R. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. USA 2003, 100:8211-8216.
39. Zhang A., Zheng C., Hou M., Lindvall C., Wallin K.L., Angstrom T., Yang X., Hellstrom A.C., Blennow E., Bjorkholm M., Zetterberg A., Gruber A., Xu D. Amplification of the telomerase reverse transcriptase (hTERT) gene in cervical carcinomas. Genes Chromosomes Cancer 2002, 34:269-275.
40. Zhang D.K., Ngan H.Y., Cheng R.Y., Cheung A.N., Liu S.S., Tsao S.W. Clinical significance of telomerase activation and telomeric restriction fragment (TRF) in cervical cancer. Eur. J. Cancer 1999, 35:154-160.